ArticlePloS one2014
Expression of the EGF family in gastric cancer: downregulation of HER4 and its activating ligand NRG4.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- HER3, but Not HER4, Plays an Essential Role in the Clinicopathology and Prognosis of Gastric Cancer: A Meta-Analysis.PloS one · 2016Pooled it
- The journey towards physiology and pathology: Tracing the path of neuregulin 4.Genes & diseases · 2024Review
- The Role of Adipokines and Myokines in the Pathogenesis of Different Obesity Phenotypes-New Perspectives.Antioxidants (Basel, Switzerland) · 2023Review
- Glucose upregulates amphiregulin in oral dysplastic keratinocytes: A potential role in diabetes-associated oral carcinogenesis.Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology · 2023Article
- Prognostic biomarkers and molecular pathways mediating Helicobacter pylori-induced gastric cancer: a network-biology approach.Genomics & informatics · 2023Article
- Effects of HFrontiers in oncology · 2022Article
- Focal amplifications are associated with chromothripsis events and diverse prognoses in gastric cardia adenocarcinoma.Nature communications · 2021Article
- A signature of seven immune-related genes predicts overall survival in male gastric cancer patients.Cancer cell international · 2021Article
- Alternative Splicing Events in Tumor Immune Infiltration in Colorectal Cancer.Frontiers in oncology · 2021Article
- Eradication ofFrontiers in microbiology · 2021Review
- Neuregulins in Neurodegenerative Diseases.Frontiers in aging neuroscience · 2021Article
- Machine-learning based radiogenomics analysis of MRI features and metagenes in glioblastoma multiforme patients with different survival time.Journal of cellular and molecular medicine · 2019Article
- Distinct expression and prognostic value of members of the epidermal growth factor receptor family in ovarian cancer.Cancer management and research · 2018Article
- Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines.Journal of cancer research and clinical oncology · 2017Article
- Preventing High Fat Diet-induced Obesity and Improving Insulin Sensitivity through Neuregulin 4 Gene Transfer.Scientific reports · 2016Article
- Tumor suppressor microRNA-31 inhibits gastric carcinogenesis by targeting Smad4 and SGPP2.Cancer gene therapy · 2015Article
- MicroRNA let-7b suppresses human gastric cancer malignancy by targeting ING1.Cancer gene therapy · 2015Article
- Nucleostemin regulates proliferation and migration of gastric cancer and correlates with its malignancy.International journal of clinical and experimental medicine · 2015Article
- The up-regulation of miR-300 in gastric cancer and its effects on cells malignancy.International journal of clinical and experimental medicine · 2015Article
- MicroRNA-126 regulates migration and invasion of gastric cancer by targeting CADM1.International journal of clinical and experimental pathology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer is a major cause of cancer-related deaths in both men and women. The epidermal growth factor receptors are EGFR, HER2, HER3 and HER4. Of the four epidermal growth factor receptors, EGFR and HER2 are well-known oncogenes involved in gastric cancer. Little, however, is known about the role played by HER3 and HER4 in this disease. We obtained paired samples from the tumor and the adjacent normal tissue from the same patient undergoing surgery for gastric cancer. Using RT-qPCR, we quantified the mRNA expression of the four receptors including the HER4 splicing isoforms and all the ligands activating these receptors. Using immunohistochemistry, the protein expression of HER4 was also quantified. We found that HER2 mRNA expression was upregulated in the tumor tissue compared to the matched normal tissue (p = 0.0520). All ligands with affinity for EGFR were upregulated, whereas the expression of EGFR was unchanged. Interestingly, we found the mRNA expression of HER4 (p = 0.0002) and its ligand NRG4 (p = 0.0009) to be downregulated in the tumor tissue compared to the matched normal tissue. HER4 downregulation was demonstrated for all the alternatively spliced isoforms of this receptor. These results support the involvement of EGFR and HER2 in gastric cancer and suggest an interesting association of reduced HER4 expression with development of gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.